Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Entered into a definitive agreement to acquire 100% of Kashiv BioSciences for $375M cash and $375M equity at closing, plus up to $350M in milestone payments and ongoing royalties tied to product performance.

• The acquisition aims to create a fully integrated global biosimilars platform, leveraging Kashiv’s R&D and manufacturing with commercial scale, targeting the $300B+ global biologics LOE opportunity.

• The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.

• Preliminary Q1 2026 results show strong growth, with net revenue up 4% year-over-year and significant increases in net income and adjusted EBITDA.

• Full-year 2026 standalone guidance was raised, reflecting continued momentum and anticipated benefits from the acquisition.

Voting matters and shareholder proposals

• Shareholder approval is required for the issuance of equity consideration and the acquisition agreement.

• Proxy statement and related materials will be filed with the SEC; shareholders are urged to review these documents when available.

• The transaction is subject to approval by a majority of votes cast by disinterested shareholders.

Board of directors and corporate governance

• An independent Conflicts Committee of the Board, composed of five independent directors, negotiated and approved the transaction, determining it to be fair and in the best interests of shareholders.

• The Board unanimously recommended shareholder approval of the transaction.

• Amendment to the Stockholders Agreement will be executed at closing to update definitions and governance terms.